Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 64, Issue 8, Pages 756-762Publisher
ELSEVIER
DOI: 10.1016/j.addr.2011.11.009
Keywords
T cell receptor; Gene therapy; Cancer immunotherapy
Categories
Funding
- Intramural NIH HHS [Z99 CA999999] Funding Source: Medline
- NCI NIH HHS [Y99 CA999999] Funding Source: Medline
Ask authors/readers for more resources
In the past two decades, human gene transfer research has been translated from a laboratory technology to clinical evaluation. The success of adoptive transfer of tumor-reactive lymphocytes to treat the patients with metastatic melanoma has led to new strategies to redirect normal T cells to recognize tumor antigens by genetic engineering with tumor antigen-specific T cell receptor (TCR) genes. This new strategy can generate large numbers of defined antigen-specific cells for therapeutic application. Much progress has been made to TCR gene transfer systems by optimizing gene expression and gene transfer protocols. Vector and protein modifications have enabled excellent expression of introduced TCR chains in human lymphocytes with reduced mis-pairing between the introduced and endogenous TCR chains. Initial clinical studies have demonstrated that TCR gene-engineered T cells could mediate tumor regression in vivo. In this review, we discuss the progress and prospects of TCR gene-engineered T cells as a therapeutic strategy for treating patients with melanoma and other cancers. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available